Mivebresib, also known as ABBV-075, is an inhibitor of bormodomain and extra terminal domain (BET). The Ki values of BRD2, BRD4, BRDT are 1 nM - 2.2 nM.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
产品名称 | BET ↓ ↑ | bromodomain ↓ ↑ | BRPF ↓ ↑ | CBP/beta-catenin ↓ ↑ | p300/CBP ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MS436 |
++
BRD4 (1), Ki: <0.085 μM BRD4 (2), Ki: 0.34 μM |
99%+ | |||||||||||||||||
CPI-203 |
+++
BRD4, IC50: 37 nM |
98+% | |||||||||||||||||
GSK1324726A |
+++
BRD4, IC50: 22 nM BRD2, IC50: 31 nM |
99%+ | |||||||||||||||||
PFI-1 |
++
BRD4, IC50: 0.22 μM BRD2, IC50: 98 nM |
98% | |||||||||||||||||
Apabetalone |
+
BD2, IC50: 0.51 μM |
99% | |||||||||||||||||
(+)-JQ1 |
+++
BRD4 (1), IC50: 77 nM BRD4 (2), IC50: 33 nM |
98% | |||||||||||||||||
I-BET151 |
+
BRD4, IC50: 0.5 μM BRD3, IC50: 0.25 μM |
98% | |||||||||||||||||
Molibresib |
+++
BET proteins, IC50: 35 nM |
99%+ | |||||||||||||||||
I-BRD9 |
+++
BRD4, pIC50: 5.3 BRD9, pIC50: 7.3 |
99%+ | |||||||||||||||||
BI-7273 |
++++
BRD7, IC50: 117 nM BRD9, IC50: 19 nM |
99+% | |||||||||||||||||
Pelabresib |
+++
BRD4-BD1, IC50: 39 nM |
98% | |||||||||||||||||
ARV-825 |
+++
BRD4 BD2, Kd: 28 nM BRD4 BD1, Kd: 90 nM |
99%+ | |||||||||||||||||
Birabresib | 99%+ | ||||||||||||||||||
BI 2536 |
+++
BRD4, Kd: 37 nM |
c-Myc | 99%+ | ||||||||||||||||
Bromosporine |
++
BRD2, IC50: 0.29 μM BRD9, IC50: 0.122 μM |
++++
CECR2, IC50: 17 nM |
99%+ | ||||||||||||||||
XMD8-92 |
++
BRD4 (1), Kd: 170 nM |
99%+ | |||||||||||||||||
Mivebresib | ✔ | 99%+ | |||||||||||||||||
BI-9564 |
++++
BRD7, Kd: 73 nM BRD9, Kd: 5.9 nM |
++
CECR2, Kd: 77 nM |
98% | ||||||||||||||||
AZD5153 6-Hydroxy-2-naphthoic acid |
++++
FL-BRD4, IC50: 5 nM |
99%+ | |||||||||||||||||
PLX51107 |
++++
BRD4 BD2, Kd: 1.7 nM BRD3 BD1, Kd: 2.1 nM |
99%+ | |||||||||||||||||
FL-411 |
+
BRD4(1), IC50: 0.43 μM |
99%+ | |||||||||||||||||
ABBV-744 | ✔ | 99%+ | |||||||||||||||||
dBET6 |
++++
BRD4, IC50: 14 nM |
99%+ | |||||||||||||||||
dBET1 |
++++
BRD4, IC50: 20 nM |
99%+ | |||||||||||||||||
MZ1 |
++++
Brd2(BD2), Kd: 62 nM Brd3(BD2), Kd: 13 nM |
99%+ | |||||||||||||||||
dBET57 |
+
BRD4BD1, DC50: 500 nM |
99%+ | |||||||||||||||||
SF2523 |
+
BRD4, IC50: 241 nM |
DNA-PK | 99%+ | ||||||||||||||||
INCB054329 |
++++
BRD3-BD1, IC50: 9 nM BRD4-BD1, IC50: 119 nM |
99% | |||||||||||||||||
INCB-057643 | ✔ | 99%+ | |||||||||||||||||
(E/Z)-ZL0420 |
+++
BRD4 BD2, IC50: 32 nM BRD4 BD1, IC50: 27 nM |
99%+ | |||||||||||||||||
BMS-986158 | ✔ | 99%+ | |||||||||||||||||
BRD4 Inhibitor-10 |
++++
BRD4-BD1, IC50: 5 nM BRD4-BD2, IC50: 41 nM |
97% | |||||||||||||||||
A1874 | ✔ | 99%+ | |||||||||||||||||
Y06036 |
++
BRD4 (1), Kd: 82 nM |
99%+ | |||||||||||||||||
Alobresib | ✔ | NF-κB | 98% | ||||||||||||||||
ODM-207 | ✔ | 99% | |||||||||||||||||
GSK778 |
+++
BRD4-BD1, IC50: 143 nM BRD2-BD1, IC50: 75nM |
97% | |||||||||||||||||
SRX3207 |
+
BRD42, IC50: 3070 nM BRD41, IC50: 3070 nM |
Syk | 98% | ||||||||||||||||
GSK046 |
+++
BRD4BD2, IC50: 214 nM BRD3BD2, IC50: 98 nM |
98% | |||||||||||||||||
GSK620 | ✔ | 97% | |||||||||||||||||
Thalidomide-NH-C4-NH-Boc | ✔ | 98% | |||||||||||||||||
Trotabresib | ✔ | 99% | |||||||||||||||||
NHWD-870 | ✔ | 98% | |||||||||||||||||
CFT8634 |
++++
BRD9, DC50: 3 nM |
98% | |||||||||||||||||
GSK2801 |
++
BAZ2B, Kd: 136 nM BAZ2A, Kd: 257 nM |
99%+ | |||||||||||||||||
KG-501 | ✔ | 99%+ | |||||||||||||||||
UNC 669 |
+
L3MBTL4, IC50: 6 μM L3MBTL3, IC50: 35 μM |
98% | |||||||||||||||||
PFI-3 |
+++
SMARCA4, Kd: 55 nM SMARCA2A, Kd: 72 nM |
99%+ | |||||||||||||||||
UNC1215 |
+++
L3MBTL3- D274A, IC50: 3.5 μM L3MBTL3, IC50: 120 nM |
99%+ | |||||||||||||||||
EED226 |
++
EED, Kd: 82 nM PRC2, Kd: 114 nM |
99%+ | |||||||||||||||||
BRD9539 | ✔ | 98% | |||||||||||||||||
UNC926 |
+
L3MBTL1, Kd: 3.9 μM |
99% | |||||||||||||||||
666-15 |
++
CREB, IC50: 81 nM |
99%+ | |||||||||||||||||
UNC6852 |
+
EED, IC50: 247 nM |
98% | |||||||||||||||||
BAZ1A-IN-1 |
+
BAZ1A, Kd: 0.52 μM |
99%+ | |||||||||||||||||
PFI-4 |
++
BRPF2, IC50: 7.9 μM BRPF1, IC50: 80 nM |
99%+ | |||||||||||||||||
OF-1 |
++
BRPF2, Kd: 500 nM BRPF1B, Kd: 100 nM |
99%+ | |||||||||||||||||
GSK-5959 |
++
BRPF2, pIC50: 5.2 BRPF3, pIC50: 7.1 |
99% | |||||||||||||||||
GSK6853 |
++++
BRPF1, pIC50: 8.1 |
99%+ | |||||||||||||||||
NI-42 |
++++
BRPF1, IC50: 48 nM BRPF3, IC50: 260 nM |
99%+ | |||||||||||||||||
E-7386 |
+++
CBP/beta-catenin, IC50: 0.0484 μM |
97% | |||||||||||||||||
I-CBP112 |
++
CBP, Kd: 151 nM p300, Kd: 167 nM |
98+% | |||||||||||||||||
Histone Acetyltransferase Inhibitor II |
+
p300, IC50: 5 μM |
98% | |||||||||||||||||
C646 |
+
p300/CBP, Ki: 400 nM |
99%+ | |||||||||||||||||
Anacardic Acid |
+
PCAF, IC50: 5 μM p300/CBP, IC50: 8.5 μM |
99%+ | |||||||||||||||||
SGC-CBP30 |
++++
CREBBP, IC50: 21 nM EP300, IC50: 38 nM |
99%+ | |||||||||||||||||
Nordihydroguaiaretic acid | ✔ | HER2,IGF-1R | 99%+ | ||||||||||||||||
Curcumin |
+
p300, IC50: ~25 μM |
Ferroptosis,Nrf2,NF-κB | 98% | ||||||||||||||||
PF-CBP1 HCl |
++
CREBBP, IC50: 125nM p300/CBP, IC50: 363nM |
97% | |||||||||||||||||
CPI-637 |
+++
EP300, IC50: 0.051 μM CBP, IC50: 0.03 μM |
99%+ | |||||||||||||||||
Foscenvivint | ✔ | β-catenin | 99%+ | ||||||||||||||||
A-485 |
++
p300 HAT, IC50: 0.06 μM |
99%+ | |||||||||||||||||
GNE-781 |
+
BRD4(1), IC50: 5100 nM |
++++
CBP, IC50: 0.94 nM |
98% | ||||||||||||||||
NEO2734 |
+++
BET, IC50: <30 nM |
+++
p300/CBP, IC50: <30 nM |
99%+ | ||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
靶点 |
|
描述 | Mivebresib is a potent and selective inhibitor of the bromodomain and extra terminal domain family of proteins. It binds to the bromodomains of BRD2/4/T with Ki values of 1-2.2nM. It also exhibits 10-fold weaker potency for BRD3 with a Ki value of 12.2nM. Mivebresib is highly selective for 18 bromodomain proteins with Kd values >1μM ( >600-fold selectivity versus BRD4). It displayed moderate activity towards CREBBP with a Kd value of 87μM (54-fold selectivity versus BRD4). Mivebresib showed robust single agent activity in cancer cell lines derived from lymphomas, leukemia, and solid tumors. It disrupted cell cycle control of cancer cells, inhibiting apoptosis and oncogenesis[3]. Mivebresib inhibited DHT-stimulated transcription of androgen receptor (AR) target genes without affecting the protein expression of AR. It disrupted DHT-stimulated recruitment of BRD4 to gene regulatory regions co-occupied by AR. Mivebresib also inhibited MYC and TMPRSS2-ETS fusion proteins with high potency[4]. In flank xenograft mouse models, mivebresib exhibited potent anti-tumor activity comparable or superior to standard-of-care agents[3]. |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.18mL 0.44mL 0.22mL |
10.88mL 2.18mL 1.09mL |
21.76mL 4.35mL 2.18mL |
CAS号 | 1445993-26-9 |
分子式 | C22H19F2N3O4S |
分子量 | 459.466 |
别名 | ABBV-075 |
运输 | 蓝冰 |
存储条件 |
液体 -20°C:3-6个月-80°C:12个月 粉末 Sealed in dry,2-8°C |
溶解度 |
DMSO: 105 mg/mL(228.53 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO |
动物实验配方 |